News

Texoma Medical Center now offers a proven, non-invasive diagnostic option for people with suspected heart disease living in the Texoma region. Using CT images combined with CT-derived fractional flow reserve (FFRCT) is a noninvasive clinical pathway that helps diagnose CAD. Trained analysts and AI algorithms create an anatomical model of a person’s heart that helps physicians visualize the blood flow and detect stenosis, or plaque that obstructs the blood flow. Heart disease is the leading cause of death for adults in the United States, and CAD is the most common type of heart disease, affecting nearly half the adult population. CAD develops when the arteries leading to the heart narrow or become blocked, which may lead to a reduction in blood flow to the heart. This can cause chest pain, heart attacks and death. Identifying exactly where and how an artery is blocked or clogged can help improve a person’s treatment plan, including whether or not an intervention is needed.

Despite CAD being the most common form of heart disease, studies have shown there is a need to improve how and when CAD is evaluated and diagnosed. Many of the non-invasive tests available today offer a low accuracy rate in detecting CAD. About 4 million diagnostic tests are conducted on patients with chest pain suspected of having CAD each year in the U.S., many of which are unnecessary. “Historically, we have been faced with either using tests that were occasionally inconclusive or putting a patient through an invasive procedure just to determine whether they would need another invasive procedure to restore blood flow,” said Dr. Wael AboAudo, MD, FACC, an Interventional Cardiologist at TMC. “The HeartFlow FFRCT Analysis completely changes this paradigm, providing essential information that can help us determine the right approach for a patient through a convenient, non-invasive platform.”

Recognized by professional guidelines and backed by data, The HeartFlow FFRCT Analysis offers the highest diagnostic accuracy available from a noninvasive test. Additionally, in clinical trials, using the HeartFlow FFRCT Analysis helped identify which patients do and do not need invasive treatment. The use of the HeartFlow FFRCT Analysis also reduced the cost of care by 26% compared to usual care. Professional guidelines, such as the ACC/AHA chest pain guidelines, recognize the combination of CCTA with selective FFRCT as a front-line pathway that helps diagnose CAD. This pathway was recently shown to be the superior diagnostic pathway in the PRECISE trial for suspected CAD compared to traditional testing.

According to Maziar Mahjoobi, DO, FACC, FSCAI, an Interventional Cardiologist at TMC, “The HeartFlow FFRCT Analysis will help us develop the most appropriate treatment plan for a patient with coronary artery disease without the need for unnecessary and stressful procedures. This is game-changing technology that will be beneficial for both our patients and our hospital.”